Metastatic liver cancer is also known as secondary liver cancer or liver metastases. It is caused by the metastasis of malignant tumors from all organs of the body to the liver due to the anatomical and histological characteristics of the liver. The liver is an extremely suitable organ for the growth of tumor cells and is one of the organs most prone to metastatic tumor formation. Liver metastasis eventually occurs in about 80% of patients with advanced tumors. Gastrointestinal tumors are most likely to develop liver metastasis, accounting for about 60% to 70% of liver metastases, followed by breast cancer, lung cancer, esophageal cancer, pancreatic cancer, gallbladder cancer, bile duct cancer, lung cancer, kidney cancer, bladder cancer, ovarian cancer, soft tissue tumors, etc. The treatment of metastatic liver cancer includes systemic treatment and local treatment: systemic treatment is mainly chemotherapy and molecular targeted therapy for various tumors. Local treatment includes surgery, minimally invasive ablation therapy, radiotherapy and so on. Local treatment is very important, because no matter chemotherapy or molecular targeted therapy will eventually be resistant and lose its therapeutic effect. There have been a lot of clinical data confirming that if tumors can be well controlled locally, their survival will be significantly extended. Minimally invasive ablation therapy (microwave and radiofrequency) has outstanding advantages, which is suitable for one or more metastases and can be repeatedly treated with less pain, faster recovery and better efficacy.